Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Oh, Heeyoung; Menéndez, Ángeles Flórez; Santos, Víctor Sacristán; Ribeiro, Francisca Fernández; Vilanova-Trillo, Lucía; Figueiras, Manuel Constenla; Ferreiros, Manuel Pereiro

doi:10.7573/dic.2020-6-6

Cited by 4 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results show a significant improvement in patients' QoL over the 3-month followup period. The impact of dermatological toxicities on patients' QoL has been seldom investigated [17,18,22], representing an unmet clinical need. Cutaneous toxicities are usually nonlife-threatening and self-limited in time [23]; nevertheless, their physical, emotional and psychosocial burden cannot be neglected.…”

Section: Discussionmentioning

confidence: 99%

Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy

Mannino,

Sollena,

Di Stefani

et al. 2024

Dermatology

View full text Add to dashboard Cite

Background: novel oncologic therapies, including epidermal growth factor receptor inhibitors (EGFR-Is) and immune checkpoint inhibitors (ICIs), are associated with a new spectrum of adverse reactions, with prominent cutaneous toxicities. The impact of cutaneous adverse events (cAEs) on patients’ quality of life (QoL) represents an unmet clinical need. Objectives: 1) to assess whether cutaneous toxicities directed therapies are effective in reducing the QoL burden via the submission of two patient reported outcome measures (PROMs); 2) to investigate whether class of oncologic therapy, type of cAE and toxicity severity differently impact on patients’ QoL. Methods: a prospective observational study was conducted at the Dermatology department of the Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, from October 2018 to October 2019. Patients aged ≥ 18 years, under therapy with EGFR-Is or ICIs and experiencing a treatment-related cAE were eligible for the study. Dermatology Life Quality Index (DLQI) and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire– Core 30 version 3.0 (EORTC QLQ-C30) were administered to patients at first clinical visit (T0), at 1-month (T1), and at 3-month (T2) dermatological follow-up. Results: Sixty cAEs of 51 patients have been recorded. A significant difference in the mean score for both DLQI and EORTC QLQ-C30 was found along the 3-months dermatological follow-up (p <0.0001). A similar QoL improvement was reported for PROMs stratified by class of therapy and toxicity severity (p <0.0001). No difference was reported for patients with pyogenic granuloma-like lesions and psoriasiform eruption as per DLQI. Class of therapy and toxicity severity did not differently impact on patients’ QoL at selected timepoints; we reported a higher EORTC QLQ-C30 score at T2 for patients developing psoriasiform eruption compared to other types of cAEs. Conclusions: Early patients’ referral to dermatologists and tailored management could result in better QoL.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy

Mannino,

Sollena,

Di Stefani

et al. 2024

Dermatology

View full text Add to dashboard Cite

show abstract

“…We know that cutaneous toxicities diminish the quality of life (QoL) of patients, which impacts their treatment adherence and can affect their personal, social, and workplace relationships, jeopardizing the treatment's success and patient survival ( 12 ). Notably, their frequency and severity may be associated with clinical benefit from anticancer therapies; thus, mitigating these events is of importance to maintaining dose intensity and QoL.…”

Section: Discussionmentioning

confidence: 99%

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response

et al. 2023

View full text Add to dashboard Cite

Cancer treatment-related adverse events (AEs) are sometimes associated with outcomes for cancer patients, especially with the newest therapies such as target therapy and immunotherapy. A few years ago, the first-line therapy for hormone-receptor-positive metastatic breast cancer (mBC) patients has been deeply changed by the introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors, and now, we are improving our knowledge about their AEs and significance in clinical practice. Here, we report our experience with two cases of vitiligo-like lesions that occur early during treatment with ribociclib. We tried to change the CDK4/6 inhibitor for one patient, but the skin reaction persisted. Both patients retained only the endocrine therapy alone and had an unexpected durable progression-free survival (PFS). Some data on skin toxicities, including vitiligo-like lesions by CDK4/6 inhibitors, have recently been reported in the literature, but for the first time, we highlight a possible correlation with improved survival outcomes of patients. Uncovering the etiology of this toxicity, verifying the involvement of the immune system, and demonstrating a possible positive impact in survival represent an intriguing research objective for the near future.

show abstract

“…Cancer therapy also has a significant impact on the quality of life of patients. They struggle with a sense of discomfort associated with pain and itching [8].…”

Section: Introductionmentioning

confidence: 99%

Immune Reactions in Major Types of Oncological Treatment

Kozubek,

Wołoszczak,

Gomułka

2023

IJMS

View full text Add to dashboard Cite

In recent years, there has been a noticeable development in oncological treatment, including chemotherapy and biological treatment. Despite their significant effectiveness, they are not free from side effects, such as allergic and dermatological reactions. These reactions can vary in severity and outcome, including potential death. Examples, among others, are type I-IV hypersensitivity reactions of various origins and skin reactions including rashes, itching and redness, but also severe cutaneous syndromes. Due to the therapy used, these may include Stevens–Johnson syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, drug-induced hypersensitivity syndrome and acute generalized exanthematous pustulosis. In some cases, it is necessary to interrupt therapy, which may result in a poorer outcome and shorten the patient’s survival. This paper reviews various types of research documents published since 2016. It aims to systematize the latest knowledge and highlight the need for further research into ways to avoid adverse reactions.

show abstract

Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study

Cited by 4 publications

References 33 publications

Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy

Quality of Life Impact in Patients with Cutaneous Toxicities Caused by Epidermal Growth Factor Receptor Inhibitors and Immunotherapy

Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response

Immune Reactions in Major Types of Oncological Treatment

Contact Info

Product

Resources

About